Go to the list of all blogs
Rick Johnson's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Aligos Therapeutics (ALGS): Examining a Biotech's Focus on Liver Diseases

Aligos Therapeutics (ALGS): Examining a Biotech's Focus on Liver Diseases

Key Takeaways

  • Aligos Therapeutics, Inc. (ALGS) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and viral diseases.
  • The company is headquartered in South San Francisco, California, was incorporated in 2018, and completed its initial public offering (IPO) on Nasdaq in October 2020.
  • Its pipeline is anchored by drug candidates targeting chronic hepatitis B, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.
  • As a clinical-stage company, Aligos generates limited product revenue and relies primarily on financing activities to fund research and development.
  • The stock carries significant risk typical of early-stage biotechnology, including clinical trial uncertainty and the need for future capital.

Introduction

Aligos Therapeutics, Inc. (ALGS) develops novel therapeutics aimed at chronic liver diseases and viral infections. As a research-driven, pre-commercial enterprise, its value hinges almost entirely on the advancement of experimental drug candidates. I follow the company because its pipeline targets large patient populations in hepatitis B and metabolic liver disease, where clear unmet needs remain.

Company Background

Aligos was incorporated in 2018 and is based in South San Francisco, California. Dr. Lawrence M. Blatt leads the company as Chief Executive Officer, President, and Chairman. It went public on Nasdaq in October 2020. The business model centers on proprietary small-molecule and oligonucleotide therapies for liver and viral conditions. With no approved products yet, revenue has come mainly from modest collaboration and licensing deals rather than sales.

Key programs include candidates for chronic hepatitis B such as ALG-000184 and pevifoscorvir sodium, ALG-055009 for MASH and obesity, and ALG-097558 for coronaviruses. Research ties with institutions like Emory University and Katholieke Universiteit Leuven support discovery work. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Competition comes from larger players in similar areas.

Why Investors Follow ALGS

Attention centers on the high-need disease areas. Chronic hepatitis B impacts tens of millions worldwide, with existing treatments seldom delivering a functional cure. MASH, tied to obesity and diabetes, offers another sizable market with few approved options. The focused pipeline creates a clear investment case. Clinical readouts and regulatory steps drive long-term value, potentially opening doors to partnerships.

Risks and Important Considerations

Clinical-stage biotech investing brings standard risks. Candidates lack approval, and trial success is never assured. Development is expensive and lengthy, so any setback could affect the outlook materially. Aligos has posted net losses with limited revenue, depending on future capital raises that may dilute shareholders. Its small market cap and share-price volatility add to the profile. Intense competition from bigger firms in hepatitis B and MASH spaces, along with regulatory or technological shifts, further shapes the landscape.

Conclusion

Aligos remains a focused clinical-stage player addressing unmet needs in liver and viral diseases. Its pipeline emphasis on hepatitis B, MASH, and coronaviruses sets a distinct position, yet pre-commercial status and reliance on clinical outcomes keep the outlook uncertain. From what I see, this represents a high-risk, high-reward profile driven by scientific progress rather than near-term sales.

Exploring Tickeron’s AI Screener

I find Tickeron’s AI Screener helpful when reviewing biotech names like this one. It lets me apply technical indicators, fundamentals, volatility measures, trends, and AI signals to narrow down ideas quickly. The platform supports building a custom watchlist that fits a personal strategy, which has been useful for comparing opportunities in the sector without sifting through everything manually.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ALGS

ALGS in upward trend: price may jump up because it broke its lower Bollinger Band on November 06, 2026

ALGS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 35 cases where ALGS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +9.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALGS advanced for three days, in 186 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALGS as a result. In 85 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for ALGS turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 44 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALGS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for ALGS entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.797) is normal, around the industry mean (3.592). P/E Ratio (-0.528) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (1.680) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. ALGS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALGS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -10%. For the same Industry, the average monthly price growth was -9%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 129%, while CUE experienced the biggest fall at -85%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 10% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
One Corporate Drive
Phone
+1 800 466-6059
Employees
82
Web
https://www.aligos.com
Interact to see
Advertisement
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.
NVIDIA reported revenue of $115.84 billion for the third quarter of fiscal 2027, up 103% year over year and ahead of both company guidance and consensus estimates. Non-GAAP earnings per share (EPS, a measure of profit per outstanding share) came in at $2.68 , beating the roughly $2.47 analysts had expected.